title: United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall
source: Yahoo
date: 2025-10-23
url: https://finnhub.io/api/news?id=c71cd6e181f0deeeb69881f06ea43c4f632fd7742a51c44af85236f556c4c0bc
The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving this growth include an aging population, heightened smoking rates, and environmental influences. The demand for innovative inhalers, biologics, and rehabilitation programs is rising. Key segments include chronic bronchitis and emphysema, with treatment options spanning drugs, oxygen therapy, and surgery. States l
